Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease.
Antiretroviral therapy (ART), while essential in combatting tuberculosis (TB) and HIV coinfection, is often complicated by the TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). Depending on the TB disease site and treatment status at ART initiation, this immune-mediated worsening of TB pathology can take the form of paradoxical TB-IRIS, unmasking TB-IRIS, or CNS TB-IRIS. Each form of TB-IRIS has unique implications for diagnosis and treatment. Recently published studies have emphasized the importance of neutrophils and T cell subtypes in TB-IRIS pathogenesis, alongside the recognized role of CD4 T cells and macrophages. Research has also refined our prognostic understanding, revealing how the disease can impact lung function. While corticosteroids remain the only trial-supported therapy for prevention and management of TB-IRIS, increasing interest has been given to biologic therapies directly targeting the immune pathology. TB-IRIS, especially its unmasking form, remains incompletely described and more data is needed to validate biomarkers for diagnosis. Management strategies remain suboptimal, especially in the highly morbid central nervous system (CNS) form of the disease, and further trials are necessary to refine treatment. In this review we will summarize the current understanding of the immunopathogenesis, the presentation of TB-IRIS and the evidence for management recommendations.
['Quinn|Carson M|CM|0000-0001-8858-8563', 'Poplin|Victoria|V|', 'Kasibante|John|J|0000-0002-7252-4052', 'Yuquimpo|Kyle|K|', 'Gakuru|Jane|J|0000-0003-0150-4887', 'Cresswell|Fiona V|FV|0000-0002-5070-532X', 'Bahr|Nathan C|NC|0000-0002-9431-8938']
tuberculosis immune reconstitution inflammatory syndrome acquired immunodeficiency syndrome tuberculous meningitis